Moderna's Q1: Big COVID Deals, Cost Cuts, FDA Nods

Modernas Q1 revenue skyrocketed to $389 million, surpassing expectations by 260%, driven by international COVID vaccine deals, particularly in the UK. The company cut adjusted cash costs by 26% and beat earnings per share estimates. Despite initial market dip due to a heavy litigation settlement, investors are focusing on future catalysts, including FDA approvals for flu vaccine and combo shots, and late-stage data from oncology trials. The stock is holding steady around $48.62 as the company pivots beyond COVID. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/938c8e9c80599ef6